Send to

Choose Destination
Ther Adv Urol. 2018 Oct 26;10(12):377-381. doi: 10.1177/1756287218808677. eCollection 2018 Dec.

Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/chronic pelvic pain syndrome.

Author information

Department of Urology, ASST-Rhodense, Milan, Viale C. forlanini 95, Garbagnate Milanese, 20024, Italy.
Urology Department, Madonna delle Grazie Hospital, Velletri, Rome, Italy.
Urology Department, ASST-Rhodense, Garbagnate, Milan, Italy.
Urology Department, Fabia Mater Hospital, Rome, Italy.



Chronic prostatitis/chronic pelvic pain syndrome (IIIB CP/CPPS) is a condition of unclear aetiology. Many approaches have been used without satisfactory results. The aim of this study is to evaluate the efficacy of once-daily 5 mg tadalafil in pain control and improving quality of life in patients affected by CP/CPPS.


Twenty patients affected by chronic prostatitis according EAU (European Association of Urology) guidelines were evaluated for once-daily 5 mg tadalafil; 14 patients were eligible for the study. The validated Italian version of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and the International Prostatic Symptom Score (IPSS) questionnaires were submitted to all the patients. Every patient underwent uroflowmetry and ultrasound prostatic volume at the beginning and at the end of the study.


All 14 patients eligible for the study reported an improvement of symptoms during therapy: statistically significant differences were reported in terms of NIH-CPSI (p < 0.000002) and IPSS (p < 0.0001) during follow-up evaluations. No statistically significant improvement of uroflowmetry parameters was reported during the treatment.


In our study the daily use of 5 mg tadalafil improves symptoms and quality of life in patients affected by CP/CPPS after 4 weeks of therapy. A larger population of patients is needed to confirm the efficacy of this therapy in CP/CPPS.


chronic pelvic pain syndrome; chronic prostatitis; tadalafil

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center